Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2006-02-14
2006-02-14
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S031000, C514S394000, C514S395000
Reissue Patent
active
RE038984
ABSTRACT:
There is described antifungal combination therapy comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent. More particularly, the invention relates to antifungal combination therapy comprising the use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346, SCH 56592; polyenes such as amphotericin B, nystatin or liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or other chitin inhibitors, elongation factor inhibitors such as sordarin and analogs thereof, mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127 or complex carbohydrate antifungal agents such as CAN-296 in combination with a pneumocandin derivative as described herein.
REFERENCES:
patent: 5030619 (1991-07-01), Hector
patent: 5348970 (1994-09-01), Schwartz et al.
patent: 5378804 (1995-01-01), Balkovec et al.
patent: 5514650 (1996-05-01), Balkovec et al.
patent: 5552521 (1996-09-01), Belyk et al.
patent: 5627153 (1997-05-01), Little, II et al.
patent: 5741775 (1998-04-01), Balkovec et al.
patent: 211 890 (1995-12-01), None
patent: WO 94/21677 (1994-09-01), None
patent: WO 94 21677 (1994-09-01), None
patent: WO 98/10782 (1998-03-01), None
patent: 98/10782 (1998-03-01), None
Franzot et al., Pneumocandin L-743,872 enhances the activities of amphotericin B and Fluconazole against Cryptococcus neoformans in vitro, Antimicrob. Agents Chemother., (1997), 41(2), 331-336 (abs.).
ICAAC Abstract No. 821, entitled Pneumocandin L-7543-872 enhances the activity of Amphotericin B and Fluconazole against Cryprococcus neoformans in vitro by S. P. Franzot, et al.
Antimicrobial Agents & Chemotherapy, pp. 1077-1081 (May 1995), by G. Abruzzo, et al.
Antimicrobial Agents & Chemotherapy, pp. 1070-1076 (May 1995), by K. Barizal, et al.
Antimicrobial Agents & Chemotherapy, vol. 41, No. 2, pp. 331-336 (1997), by S. Franzot, et al.
Antimicrobial Agents & Chemotherapy, vol. 41, No. 10, pp. 2310-2311 (1997), by D. Law, et al.
Antimicrobial Agents & Chemotherapy, vol. 42, No. 2, pp. 313-318 (1998), by J. Fung-Tomc, et al.
Abstracts of the 36th ICAAC, Sep. 15-18, 1996, Tuesday, Session 83, p. 132.
Abstracts of the 37th ICAAC, Sep. 28-Oct. 1, 1997, pp. 162-163.
Abruzzo, et al., Antimicrobial Agents & Chemotherapy (May 1995), pp. 1077-1081.
Franzot, et al. ICAAC Abstract No. 821, entitled “Pneumocandin L-743,872 enhances the activity of Amphotericin B and Fluconazole againstCryptococcus neoformansin vitro”.
Fung-Tomc, J., et al. Antimicrobial Agents & Chemotherapy, vol. 42, No. 2, pp. 313-318, 1998.
Law, D., et al. Antimicrobial Agents & Chemotherapy, vol. 41, No. 10, pp. 2310-2311, 1997.
Abstracts of the 36th ICAAC, Sep. 18-Oct. 1, 1997, pp. 162-163.
Abruzzo George K.
Bartizal Kenneth F.
Flattery Feighner Amy M.
Camara Valerie J.
Daniel Mark R.
Merck & Co. , Inc.
Parr Richard S.
Weddington Kevin E.
LandOfFree
Antifungal combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antifungal combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antifungal combination therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3629175